Post-traumatic stress disorder

The Haven Detox-New England Expands Services with the Launch of a Cutting-Edge Mental Health Treatment Facility in Worcester, Massachusetts

Retrieved on: 
Monday, November 27, 2023

WORCESTER, Ma., Nov. 27, 2023 /PRNewswire/ -- The Haven Detox-New England, a leader in substance abuse treatment and a proud member of the Haven Health Management family, announces a new mental health treatment facility .

Key Points: 
  • WORCESTER, Ma., Nov. 27, 2023 /PRNewswire/ -- The Haven Detox-New England, a leader in substance abuse treatment and a proud member of the Haven Health Management family, announces a new mental health treatment facility .
  • The new facility has been meticulously designed to offer primary mental health treatment for various conditions, like anxiety, bipolar disorder, post-traumatic stress disorder, and more.
  • Under the umbrella of Haven Health Management, The Haven Detox-New England has continuously prioritized patients' mental health alongside their physical well-being.
  • For further details about The Haven Detox-New England or our new mental health treatment facility, please visit our website at https://havendetoxne.com/ .

Seelos Therapeutics Announces the Selection of SLS-002 (intranasal racemic ketamine) for Inclusion in the U.S. Department of Defense's Adaptive Platform Trial to Evaluate Potential Treatments for Post-Traumatic Stress Disorder (PTSD)

Retrieved on: 
Monday, November 27, 2023

NEW YORK, Nov. 27, 2023 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that SLS-002 (intranasal racemic ketamine) has been selected for inclusion in an adaptive platform trial to evaluate treatments for post-traumatic stress disorder (PTSD) in active-duty service members and veterans. The trial is funded by the U.S. Department of Defense's (DOD) Defense Health Agency and led by the Warfighter Readiness, Performance, and Brain Health Project Management Office, part of the U.S. Army Medical Materiel Development Activity.

Key Points: 
  • "We would like to thank the project managers and subcontractors to this study for their tireless effort in moving this program forward.
  • In addition, the trial will evaluate several biomarkers associated with PTSD and assessments of treatment safety and tolerability.
  • "This study provides an ideal opportunity to study SLS-002 for PTSD," said Tim Whitaker, M.D., Chief Medical Officer of Seelos.
  • "The current approved pharmacologic treatments for PTSD have a number of limitations, and there remains a high unmet medical need.

World’s First Observational Trial to Assess Real-World Efficacy of MDMA Treatment

Retrieved on: 
Thursday, November 9, 2023

The University of Calgary, under the direction of Dr. Leah Mayo, Parker Research Chair in Psychedelics, will assess data pertaining to efficacy of MDMA in the treatment of PTSD under real-world circumstances.

Key Points: 
  • The University of Calgary, under the direction of Dr. Leah Mayo, Parker Research Chair in Psychedelics, will assess data pertaining to efficacy of MDMA in the treatment of PTSD under real-world circumstances.
  • This trial will generate Real World Evidence (“RWE”) on the efficacy of MDMA in the treatment of Post-Traumatic Stress Disorder which may be submitted to Health regulators, including Health Canada and Veterans Affairs Canada.
  • As the trial is Observational in nature, no patients will be dosed as part of the trial’s protocol.
  • The goal of the trial is to gather data on the efficacy of treatment for patients who are already qualified for treatment under the Special Access Program.

Canadian Psychedelic Trade Association Endorses Senate Report Calling for Research into Psychedelic-Assisted Therapy

Retrieved on: 
Wednesday, November 8, 2023

OTTAWA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- PsyCan — the not-for-profit trade association of legally-operating Canadian psychedelic companies — enthusiastically endorses a new report by the Senate of Canada Subcommittee on Veteran Affairs urging federal, provincial, and territorial governments to launch and fund a large-scale research program into psychedelic-assisted therapy.

Key Points: 
  • OTTAWA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- PsyCan — the not-for-profit trade association of legally-operating Canadian psychedelic companies — enthusiastically endorses a new report by the Senate of Canada Subcommittee on Veteran Affairs urging federal, provincial, and territorial governments to launch and fund a large-scale research program into psychedelic-assisted therapy.
  • While Canada is a leader in developing these innovative treatments, many barriers remain to patient access, and government must play an active role.
  • “This report echoes our calls for government funding into psychedelic-assisted therapy,” said PharmAla Biotech CEO and PsyCan Chair Nick Kadysh.
  • “Research on these subjects is constantly evolving and will continue to do so.

Engelstad Foundation Donates $1.5 Million Toward Wave Neuroscience’s Phase Two Trial for PTSD and TBI Treatment

Retrieved on: 
Wednesday, November 8, 2023

This significant contribution will accelerate the trial, which aims to develop and validate innovative treatments for Post-Traumatic Stress Disorder (PTSD) and Traumatic Brain Injury (TBI).

Key Points: 
  • This significant contribution will accelerate the trial, which aims to develop and validate innovative treatments for Post-Traumatic Stress Disorder (PTSD) and Traumatic Brain Injury (TBI).
  • Their ongoing FDA trial will evaluate the effectiveness of their pioneering technology, Magnetic EEG-guided Resonance Therapy™ (MeRTTM) in treating PTSD and TBI.
  • With this generous funding from the Engelstad Foundation, Wave Neuroscience will be able to accelerate the trial and potentially pave the way for groundbreaking treatment options.
  • “Wave Neuroscience is on the frontlines with such a compassionate mission - to help improve the lives of those with PTSD and TBI,” says Kris Engelstad, trustee of the Engelstad Foundation.

Military Roots Run Deep Through Family Care Center's Commitment to Breaking the Stigma Around Mental Health

Retrieved on: 
Thursday, November 9, 2023

DENVER, Nov. 8, 2023 /PRNewswire/ -- Every year, approximately 200,000 active-duty servicemen and women return to civilian life. Transitions for Veterans can be especially challenging due to shifting from the collective culture of military service to a more individualized role in society. In fact, studies indicate that 44% to 72% experience high levels of stress during the transition from military to civilian life.

Key Points: 
  • It's a growing concern, and it's the reason why Family Care Center continues its work to transform mental health care through its unique understanding of the military community.
  • "Our roots in providing expanded mental health care to the armed services came from a shared sense of duty, honor and dedication."
  • Family Care Center has worked to alleviate the challenges many Veterans encounter when trying to access mental health care.
  • To learn more about Family Care Center's comprehensive mental health services or to schedule an appointment, please visit https://fccwellbeing.com or call 888-374-5066.

Recent Research Shows that Massage Therapy Helps Veterans Coping with Chronic Pain

Retrieved on: 
Wednesday, November 8, 2023

EVANSTON, Ill., Nov. 8, 2023 /PRNewswire/ -- As we honor our U.S. veterans this week, the American Massage Therapy Association (AMTA) is sharing the latest research on the many ways massage can benefit veterans.

Key Points: 
  • EVANSTON, Ill., Nov. 8, 2023 /PRNewswire/ -- As we honor our U.S. veterans this week, the American Massage Therapy Association (AMTA) is sharing the latest research on the many ways massage can benefit veterans.
  • Explore recent research, which shows that massage therapy supports the health and well-being of our U.S. veterans.
  • Explore recent research on how massage therapy supports the health and well-being of our U.S. veterans.
  • Veterans cited pain and stress reduction/relaxation as the two most frequent reasons for using these CIH approaches.1
    Female veterans experience higher rates of chronic pain, depression and anxiety in comparison to male veterans.

Ketamine can rapidly reduce symptoms of PTSD and depression, new study finds

Retrieved on: 
Wednesday, November 8, 2023

The drug ketamine can reduce the symptoms of post-traumatic stress disorder, or PTSD, and symptoms of depression in patients as early as a day after injection.

Key Points: 
  • The drug ketamine can reduce the symptoms of post-traumatic stress disorder, or PTSD, and symptoms of depression in patients as early as a day after injection.
  • Patients receiving ketamine saw their PTSD symptoms reduced by about 25% both at one day and one week after therapy.
  • Ketamine might be an effective bridge to immediately reduce patients’ symptoms until trauma-focused psychotherapy and other antidepressants can kick in.
  • What still isn’t known
    The big unknown with using ketamine for PTSD and depressive symptoms is how often the injections are needed.

Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD

Retrieved on: 
Wednesday, November 8, 2023

ENGLEWOOD CLIFFS, NJ, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced plans to initiate a dose-ranging study of its targeted prophylactic treatment SPC-15 for the treatment of post-traumatic stress disorder (PTSD).

Key Points: 
  • ENGLEWOOD CLIFFS, NJ, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced plans to initiate a dose-ranging study of its targeted prophylactic treatment SPC-15 for the treatment of post-traumatic stress disorder (PTSD).
  • The study will identify the maximum tolerated intranasal dose of the drug and pharmacokinetic in small animals to determine the therapeutically relevant dose range.
  • In collaboration with AmplifyBio, Silo Pharma’s contract research organization (CRO) partner, the six- to eight-week non-good laboratory practice (GLP) study will include single ascending dose evaluation (phase 1) and a 7-day repeat intranasal dose toxicity and pharmacokinetic study.
  • “Determining the dose range that should be studied is an important step before taking a new drug candidate into a first-in-human trial,” said Eric Weisblum, Chief Executive Officer of Silo Pharma.

Renowned Addiction Expert and Traumatologist Releases New Book on Addiction, Trauma, and Families

Retrieved on: 
Wednesday, November 8, 2023

DENVER, Nov. 8, 2023 /PRNewswire/ -- "When the Solution Becomes the Problem: Helping Families Struggling with Addiction and Trauma" is a culmination of Dr. Barnes' 40+ years in the field of addiction therapy, family therapy, and traumatology. This book was written for families and practitioners alike, and instead of telling families "what to do" and "how to do it", it aims to help families understand why implementing expert recommendations can be so challenging.

Key Points: 
  • Michael F. Barnes, Ph.D, LAC, LPC recently released a book written for families struggling with addiction and trauma called, "When The Solution Becomes The Problem: Helping Families Struggling with Addiction and Trauma".
  • DENVER, Nov. 8, 2023 /PRNewswire/ -- "When the Solution Becomes the Problem: Helping Families Struggling with Addiction and Trauma" is a culmination of Dr. Barnes' 40+ years in the field of addiction therapy, family therapy, and traumatology.
  • This book was written for families and practitioners alike, and instead of telling families "what to do" and "how to do it", it aims to help families understand why implementing expert recommendations can be so challenging.
  • The book can be purchased on Amazon or on Dr. Barnes' website: www.drmikebarnes.com .